110 results
DEFA14A
CLSD
Clearside Biomedical Inc
26 Apr 24
Additional proxy soliciting materials
4:34pm
of the Company’s named executive officers, as disclosed in the proxy statement. 3. Ratification of the selection of Ernst & Young LLP as independent auditors
8-K
EX-10.1
eteemefloz
8 Feb 24
Clearside Biomedical Announces Pricing of $15 Million Registered
5:05pm
8-K
EX-4.1
0gzqt9wq10v5xfevvh
8 Feb 24
Clearside Biomedical Announces Pricing of $15 Million Registered
5:05pm
8-K
EX-10.2
knto tha5
8 Feb 24
Clearside Biomedical Announces Pricing of $15 Million Registered
5:05pm
424B5
k28u ruesp56j65
8 Feb 24
Prospectus supplement for primary offering
4:52pm
8-K
oy4g3smm759m6fwcj7
22 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
EX-10.1
w3h8dim 6n31pd6
12 May 23
Entry into a Material Definitive Agreement
4:11pm
S-8
EX-23.1
jdplekhbkyf
12 May 23
Registration of securities for employees
4:06pm
S-8
a8i708535129jsgk6sp9
12 May 23
Registration of securities for employees
4:06pm
DEFA14A
2w7npw xjt8hsudmv
28 Apr 23
Additional proxy soliciting materials
8:42am
8-K
EX-99.3
qg4emmwz3 v5qcaei
9 Nov 22
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
8:29am